Sunshine Biopharma Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Sunshine Biopharma Inc. (SBFM) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of $1.25 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-03.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-04-03
- Sunshine Biopharma Inc. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2021-12-31 was $667.12K.
- Sunshine Biopharma Inc. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2021-09-30 was -$4.04M.
- Sunshine Biopharma Inc. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2021-06-30 was -$2.88M.
- Sunshine Biopharma Inc. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2021-03-31 was -$6.19M.
- Sunshine Biopharma Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was $1.25M, a 11.46% increase from fiscal 2024.
- Sunshine Biopharma Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was $1.12M.
- Sunshine Biopharma Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2021 was -$12.44M.
- Sunshine Biopharma Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2020 was -$2.78M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 3 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 3 month as first filed | Income (Loss) from Continuing Operations before Income Taxes, Domestic 6 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 6 month as first filed | Income (Loss) from Continuing Operations before Income Taxes, Domestic 9 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | $1.25M 10-K · filed 2026-04-03 | |||||
| 2024-12-31 | $1.12M 10-K · filed 2026-04-03 | |||||
| 2021-12-31 | $667.12K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | -$3.37M derived: sum of 2 quarters · filed 2022-03-21 | -$6.25M derived: sum of 3 quarters · filed 2022-03-21 | -$12.44M 10-K · filed 2022-03-21 | ||
| 2021-09-30 | -$4.04M 10-Q · filed 2021-11-09 | -$6.92M derived: sum of 2 quarters · filed 2021-11-09 | -$13.10M 10-Q · filed 2021-11-09 | -$14.19M derived: sum of 4 quarters · filed 2022-03-21 | ||
| 2021-06-30 | -$2.88M 10-Q · filed 2021-08-09 | -$9.06M 10-Q · filed 2021-08-09 | -$10.15M derived: sum of 3 quarters · filed 2022-03-21 | -$10.85M derived: sum of 4 quarters · filed 2022-03-21 | ||
| 2021-03-31 | -$6.19M 10-Q · filed 2021-05-11 | -$7.27M derived: sum of 2 quarters · filed 2022-03-21 | -$7.97M derived: sum of 3 quarters · filed 2022-03-21 | -$8.87M derived: sum of 4 quarters · filed 2022-03-21 | ||
| 2020-12-31 | -$1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | -$1.78M derived: sum of 2 quarters · filed 2022-03-21 | -$2.69M derived: sum of 3 quarters · filed 2022-03-21 | -$2.78M 10-K · filed 2022-03-21 | ||
| 2020-09-30 | -$698.60K 10-Q · filed 2021-11-09 | -$1.61M derived: sum of 2 quarters · filed 2021-11-09 | -$1.70M 10-Q · filed 2021-11-09 | -$2.10M derived: sum of 4 quarters · filed 2021-11-09 | ||
| 2020-06-30 | -$907.44K 10-Q · filed 2021-08-09 | -$638.31K 10-Q · filed 2020-08-19 | -$1.00M 10-Q · filed 2021-08-09 | -$732.57K 10-Q · filed 2020-08-19 | -$1.40M derived: sum of 3 quarters · filed 2021-08-09 | -$1.75M derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | -$94.26K 10-Q · filed 2021-05-11 | -$490.88K derived: sum of 2 quarters · filed 2021-05-11 | -$841.12K derived: sum of 3 quarters · filed 2021-05-11 | -$971.88K derived: sum of 4 quarters · filed 2021-05-11 | ||
| 2019-12-31 | -$396.62K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | -$746.86K derived: sum of 2 quarters · filed 2021-03-30 | -$877.62K derived: sum of 3 quarters · filed 2021-03-30 | -$1.08M 10-K · filed 2021-03-30 | ||
| 2019-09-30 | -$350.24K 10-Q · filed 2020-11-12 | -$481.01K derived: sum of 2 quarters · filed 2020-11-12 | -$681.44K 10-Q · filed 2020-11-12 | -$1.01M derived: sum of 4 quarters · filed 2020-11-12 | ||
| 2019-06-30 | -$130.76K 10-Q/A · filed 2020-08-31 | -$331.19K 10-Q/A · filed 2020-08-31 | -$660.49K derived: sum of 3 quarters · filed 2020-08-31 | -$1.57M derived: sum of 4 quarters · filed 2020-08-31 | ||
| 2019-03-31 | -$200.43K 10-Q · filed 2020-05-18 | -$529.73K derived: sum of 2 quarters · filed 2020-05-18 | -$1.44M derived: sum of 3 quarters · filed 2020-05-18 | |||
| 2018-12-31 | -$329.30K derived: 10-K 12 month − 10-Q 9 month · filed 2020-05-01 | -$1.24M derived: sum of 2 quarters · filed 2020-05-01 | -$2.14M 10-K · filed 2020-05-01 | |||
| 2018-09-30 | -$912.83K 10-Q · filed 2019-11-13 | -$1.81M 10-Q · filed 2019-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |